A detailed history of Shell Asset Management CO transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 25,396 shares of CPRX stock, worth $523,157. This represents 0.02% of its overall portfolio holdings.

Number of Shares
25,396
Previous 28,896 12.11%
Holding current value
$523,157
Previous $448,000 12.72%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$15.19 - $21.35 $53,165 - $74,725
-3,500 Reduced 12.11%
25,396 $505,000
Q1 2024

Jul 31, 2024

SELL
$13.18 - $17.11 $24,000 - $31,157
-1,821 Reduced 5.93%
28,896 $448,000
Q1 2024

May 14, 2024

SELL
$13.18 - $17.11 $14,010 - $18,187
-1,063 Reduced 3.34%
30,717 $490,000
Q4 2023

Feb 14, 2024

SELL
$11.78 - $17.29 $112,381 - $164,946
-9,540 Reduced 23.09%
31,780 $534,000
Q3 2023

Nov 08, 2023

SELL
$11.69 - $15.02 $78,965 - $101,460
-6,755 Reduced 14.05%
41,320 $483,000
Q2 2023

Jul 28, 2023

SELL
$11.5 - $18.08 $33,419 - $52,540
-2,906 Reduced 5.7%
48,075 $646,000
Q1 2023

May 15, 2023

SELL
$14.34 - $21.05 $2,538 - $3,725
-177 Reduced 0.35%
50,981 $845,000
Q4 2022

Feb 07, 2023

SELL
$12.25 - $19.5 $130,621 - $207,928
-10,663 Reduced 17.25%
51,158 $952,000
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $114,357 - $251,392
-16,198 Reduced 20.76%
61,821 $793,000
Q2 2022

Aug 09, 2022

BUY
$6.23 - $8.57 $828 - $1,139
133 Added 0.17%
78,019 $547,000
Q1 2022

May 04, 2022

SELL
$5.31 - $8.31 $61,176 - $95,739
-11,521 Reduced 12.89%
77,886 $646,000
Q4 2021

Feb 09, 2022

BUY
$5.21 - $7.45 $2,172 - $3,106
417 Added 0.47%
89,407 $605,000
Q3 2021

Nov 04, 2021

SELL
$4.85 - $6.04 $18,527 - $23,072
-3,820 Reduced 4.12%
88,990 $472,000
Q2 2021

Aug 12, 2021

BUY
$4.29 - $6.05 $160,493 - $226,336
37,411 Added 67.53%
92,810 $534,000
Q1 2021

May 10, 2021

BUY
$3.45 - $4.69 $191,126 - $259,821
55,399 New
55,399 $255,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.12B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.